Related Experiment Video
Updated: Jun 23, 2026
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
[A novel cell model targeted on GLP-1 receptor for application to anti-diabetic candidates screening]
1Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Abstract:
The aim of this project is to establish a GLP-1 signaling pathway targeted cell model, for screening the new class of GLP-1 receptor agonists as anti-diabetic candidates. Firstly construct a recombined plasmid with multi-copied specific response element (RIP-CRE) regulated by GLP-1 signaling pathway and E-GFP reporter gene. Transient transfect this recombined plasmid into islet cell NIT-1, then detect the responsibility of transfected cell to GLP-1 analogue, Exendin 4. For secondly, use stable transfection and monocloning cell culture to obtain a GLP-1 signaling-specific cell line. It indicates that this cell model can response to Exendin 4, which response can be completely inhibited by GLP-1 receptor antagonist, Exendin 9-39, further showing GLP-1 receptor specific activity with a cAMP-PKA-independently mechanism. Establishment of this novel cell model can be used in high-throughput drug screening of peptides or small molecular GLP-1 analogues.
Insights
Researchers developed a novel cell model to screen new anti-diabetic drugs targeting the glucagon-like peptide-1 (GLP-1) receptor. This model enables high-throughput screening of potential GLP-1 receptor agonists for diabetes treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Endocrinology
Background:
- The glucagon-like peptide-1 (GLP-1) signaling pathway plays a crucial role in glucose homeostasis.
- Developing novel therapeutic agents targeting the GLP-1 receptor is a key strategy for anti-diabetic drug discovery.
- Existing screening methods may not be sufficient for identifying new classes of GLP-1 receptor agonists.
Purpose of the Study:
- To establish a robust GLP-1 signaling pathway-targeted cell model for screening novel anti-diabetic drug candidates.
- To validate the functionality and specificity of the developed cell model using known GLP-1 receptor ligands.
Main Methods:
- Construction of a recombined plasmid containing a GLP-1 responsive element (RIP-CRE) and an E-GFP reporter gene.
- Transient and stable transfection of the plasmid into NIT-1 islet cells.
- Assessment of cellular response to Exendin-4 and inhibition by Exendin-9-39.
Main Results:
- The established cell model demonstrated a measurable response to the GLP-1 analogue Exendin-4.
- The observed response was specifically inhibited by the GLP-1 receptor antagonist Exendin-9-39, confirming receptor specificity.
- The cell model's activity was found to be independent of the cAMP-PKA signaling pathway.
Conclusions:
- A novel, GLP-1 signaling-specific cell line has been successfully established.
- This cell model is suitable for high-throughput screening of novel peptide and small molecule GLP-1 analogues.
- The developed model offers a valuable tool for advancing the discovery of new anti-diabetic therapies.
